Access the full text.
Sign up today, get DeepDyve free for 14 days.
Thomas Falguières, Tounsia Aït-Slimane, C. Housset, M. Maurice (2014)
ABCB4: Insights from pathobiology into therapy.Clinics and research in hepatology and gastroenterology, 38 5
E. Spencer, Jonathan Minch, K. Lahmers, G. Haldorson, K. Mealey (2010)
Canine ABCB4: Tissue expression and cDNA structure.Research in veterinary science, 89 1
Mónika Tóth, I. Boros, E. Balint (2012)
Elevated level of lysine 9‐acetylated histone H3 at the MDR1 promoter in multidrug‐resistant cellsCancer Science, 103
Pamela Azzi, Ahmad Sharanek, A. Burban, Ruoya Li, R. Guével, Z. Abdel-Razzak, B. Stieger, C. Guguen-Guillouzo, A. Guillouzo (2015)
Comparative Localization and Functional Activity of the Main Hepatobiliary Transporters in HepaRG Cells and Primary Human Hepatocytes.Toxicological sciences : an official journal of the Society of Toxicology, 145 1
Kenneth To, O. Polgar, L. Huff, K. Morisaki, S. Bates (2008)
Histone Modifications at the ABCG2 Promoter following Treatment with Histone Deacetylase Inhibitor Mirror Those in Multidrug-Resistant CellsMolecular Cancer Research, 6
Lili Bao, S. Hazari, S. Mehra, D. Kaushal, K. Moroz, S. Dash (2012)
Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298.The American journal of pathology, 180 6
A. González-Angulo, F. Morales-Vásquez, G. Hortobagyi (2007)
Overview of resistance to systemic therapy in patients with breast cancer.Advances in experimental medicine and biology, 608
Wei Wang, Lorena Buitrago, Ying Wang (2017)
ABC transporters in megakaryopoiesis and platelet activity.Thrombosis research, 156
Daniela Číhalová, M. Ceckova, R. Kučera, J. Klimeš, F. Staud (2015)
Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro.Biochemical pharmacology, 98 3
F. Shen, S. Chu, A. Bence, Barbara Bailey, Xinjian Xue, Priscilla Erickson, M. Montrose, W. Beck, L. Erickson (2008)
Quantitation of Doxorubicin Uptake, Efflux, and Modulation of Multidrug Resistance (MDR) in MDR Human Cancer CellsJournal of Pharmacology and Experimental Therapeutics, 324
M. Yamasaki, T. Makino, T. Masuzawa, Y. Kurokawa, H. Miyata, S. Takiguchi, K. Nakajima, Y. Fujiwara, N. Matsuura, M. Mori, Y. Doki (2011)
Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinomaBritish Journal of Cancer, 104
E. Aniogo, B. George, H. Abrahamse (2017)
Phthalocyanine induced phototherapy coupled with Doxorubicin; a promising novel treatment for breast cancerExpert Review of Anticancer Therapy, 17
Z. Duan, Katherine Brakora, M. Seiden (2004)
Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells.Molecular cancer therapeutics, 3 7
Kyeong-Ah Jung, Bo-hyun Choi, M. Kwak (2015)
The c-MET/PI3K Signaling Is Associated with Cancer Resistance to Doxorubicin and Photodynamic Therapy by Elevating BCRP/ABCG2 ExpressionMolecular Pharmacology, 87
R. Januchowski, K. Wojtowicz, Małgorzata Andrzejewska, M. Zabel (2014)
Expression of MDR1 and MDR3 gene products in paclitaxel-, doxorubicin- and vincristine-resistant cell lines.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 68 1
Z Duan (2004)
833Mol Cancer Ther, 3
E. Arrigoni, S. Galimberti, M. Petrini, R. Danesi, A. Paolo (2016)
ATP-binding cassette transmembrane transporters and their epigenetic control in cancer: an overviewExpert Opinion on Drug Metabolism & Toxicology, 12
L. Goh, Kevin Spears, D. Yao, A. Ayrton, P. Morgan, C. Wolf, T. Friedberg (2002)
Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man.Biochemical pharmacology, 64 11
K. Giacomini, Shiew-Mei Huang, D. Tweedie, L. Benet, K. Brouwer, X. Chu, A. Dahlin, R. Evers, V. Fischer, K. Hillgren, K. Hoffmaster, T. Ishikawa, D. Keppler, R. Kim, Caroline Lee, M. Niemi, J. Polli, Y. Sugiyama, P. Swaan, J. Ware, S. Wright, S. Yee, M. Zamek-Gliszczynski, Lei Zhang (2010)
Membrane transporters in drug developmentNature Reviews Drug Discovery, 9
Kevin Chen, Yan Wang, M. Schaner, B. Francisco, G. Duran, D. Juric, L. Huff, H. Padilla-Nash, T. Ried, T. Fojo, B. Sikic (2005)
Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line.Cancer research, 65 20
Kenneth To, Z. Zhan, S. Bates (2006)
Aberrant Promoter Methylation of the ABCG2 Gene in Renal CarcinomaMolecular and Cellular Biology, 26
Songchang Chen, Zuwen Zhang, Jianli Zhang (2015)
Meloxicam increases intracellular accumulation of doxorubicin via downregulation of multidrug resistance-associated protein 1 (MRP1) in A549 cells.Genetics and molecular research : GMR, 14 4
T. Fojo, H. Coley (2007)
The role of efflux pumps in drug-resistant metastatic breast cancer: new insights and treatment strategies.Clinical breast cancer, 7 10
Alexander Smith, A. Helvoort, G. Meer, K. Szabó, E. Welker, G. Szakács, A. Váradi, B. Sarkadi, P. Borst (2000)
MDR3 P-glycoprotein, a Phosphatidylcholine Translocase, Transports Several Cytotoxic Drugs and Directly Interacts with Drugs as Judged by Interference with Nucleotide Trapping*The Journal of Biological Chemistry, 275
Steffen Kiehl, S. Herkt, Antje Richter, L. Fuhrmann, N. El-Nikhely, W. Seeger, R. Savai, R. Dammann (2014)
ABCB4 is frequently epigenetically silenced in human cancers and inhibits tumor growthScientific Reports, 4
A. Citti, R. Boldrini, A. Inserra, A. Alisi, R. Pessolano, A. Mastronuzzi, A. Zin, L. Sio, Angelo Rosolen, F. Locatelli, D. Fruci (2012)
Expression of multidrug resistance-associated proteins in paediatric soft tissue sarcomas before and after chemotherapy.International journal of oncology, 41 1
L. Hontecillas-Prieto, D. García-Domínguez, D. Vaca, Rosa García-Mejías, D. Marcilla, G. Ramírez-Villar, C. Sáez, E. Álava (2017)
Multidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patientsOncotarget, 8
S. Lal, A. Mahajan, W. Chen, B. Chowbay (2010)
Pharmacogenetics of target genes across doxorubicin disposition pathway: a review.Current drug metabolism, 11 1
Vlasta Němcová-Fürstová, Dana Kopperová, K. Balušíková, M. Ehrlichová, V. Brynychova, R. Vaclavikova, P. Daniel, P. Souček, J. Kovář (2016)
Characterization of acquired paclitaxel resistance of breast cancer cells and involvement of ABC transporters.Toxicology and applied pharmacology, 310
K. Livak, Thomas Schmittgen (2001)
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.Methods, 25 4
A. Nicolini, R. Giardino, Angelo Carpi, P. Ferrari, L. Anselmi, S. Colosimo, Massimo Conte, Milena Fini, G. Giavaresi, P. Berti, Paolo Miccoli (2006)
Metastatic breast cancer: an updating.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 60 9
E. Baker, R. Johnstone, J. Zalcberg, A. El-Osta (2005)
Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugsOncogene, 24
Purpose Doxorubicin is one of the most active agents in the first-line therapy for metastatic breast cancer, but its utility is partially limited by the frequent emergence of doxorubicin resistance. In this study, we aimed to investigate the role of ATP-binding cassette sub-family B, member 4 (ABCB4) in acquired doxorubicin resistance in breast cancer cells, as well as its potential mechanism. Methods In doxorubicin-sensitive and -resistant breast cancer cell lines MCF-7 and MDA-MB-231, the expression levels of ABCB4 were detected using real-time quantitative PCR and Western blot analysis, the DNA methylation and histone acetylation status of ABCB4 gene were investigated by bisulfite-sequencing PCR (BSP) and chromatin immunoprecipita- tion (ChIP) assays, and the doxorubicin sensitivity and intracellular doxorubicin accumulation were observed using cell cytotoxicity assay and flow cytometry. In Madin–Darby Canine Kidney (MDCKII) cells, In vitro transport assay was used to assess the ABCB4-mediated transport of doxorubicin. Results ABCB4 was overexpressed in doxorubicin-resistant breast cancer cells compared to their doxorubicin-sensitive counterparts, which was associated with reduced DNA methylation as well as increased histone acetylation at the ABCB4 promoter. ABCB4 could actively pump doxorubicin out of the cells, and knockdown of ABCB4 increased doxorubicin sensitivity and intracellular accumulation in doxorubicin-resistant breast cancer
Cancer Chemotherapy and Pharmacology – Springer Journals
Published: May 18, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.